Chemotherapy News and Research

Latest Chemotherapy News and Research

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

Phoenix Controls announces the introduction of APM2

Phoenix Controls, a Honeywell International business, today announced the introduction of the Advanced Pressure Monitor II (APM2), a device that monitors very low differential pressure between rooms.

21 Jan 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Gene study could result in personalized therapies for patients with deadly brain cancer

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process.

20 Jan 2010

TCGA study reveals four distinct molecular subtypes of GBM

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer Genome Atlas (TCGA) Research Network. The researchers of this study also found that response to aggressive chemotherapy and radiation differed by subtype.

20 Jan 2010

New heating therapy reduces mastectomies, kills large tumors

A new treatment developed and tested by University of Oklahoma researchers not only killed large breast cancer tumors, but reduced the need for mastectomies by almost 90 percent. The latest results appear in an upcoming issue of the Annals of Surgical Oncology.

20 Jan 2010

Sagent Pharmaceuticals introduces pamidronate disodium injection in single-dose vials

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

20 Jan 2010

European Breast Cancer Conference in Barcelona, Spain

The 7th European Breast Cancer Conference (EBCC-7) will be held in Barcelona, Spain (Centre Convencions Internacional (CCIB - FORUM), Rambla Prim 1-17, ES-08019) from Wednesday 24 - Saturday 27 March 2010.

20 Jan 2010

New research at Rhode Island Hospital identifies a treatment for glioblastomas

New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.

20 Jan 2010

New functions in an enzyme can develop through point mutation

A new study by a research team at Uppsala University shows how new functions can develop in an enzyme. This can explain, for example, how resistance to toxins can occur so simply. The findings are now being published in the Journal of Biological Chemistry.

19 Jan 2010

Bone marrow transplantation survivors can father children: new study says

Men who were previously deemed sterile due to aggressive cancer treatments may still be able to biologically father children according to a new study published in the journal, Bone Marrow Transplantation.

18 Jan 2010

FDA extends Tarceva's sNDA review period

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.

18 Jan 2010

Research reveals gene activation is linked to most aggressive type of brain cancer

Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours.

18 Jan 2010

Early diagnosis can cure endometrial cancer

Postmenopausal women who experience vaginal bleeding should see a doctor promptly. According to the January issue of Mayo Clinic Health Letter, vaginal bleeding is a symptom that occurs early in the course of endometrial cancer, when the chance of a complete cure is the greatest. Even one drop of blood is abnormal in postmenopausal women.

18 Jan 2010

Researchers identify ways to predict patients with small-cell lung cancer

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

Emmi Solutions expands existing suite of cancer-related programs in collaboration with ACS

Emmi Solutions, LLC, creators of Web-based interactive multimedia patient education programs, has collaborated with the American Cancer Society, the nation’s leading voluntary health organization and the preeminent source of cancer information and service, to expand Emmi Solutions’ existing suite of cancer-related programs.

13 Jan 2010